A Director at Jazz Pharmaceuticals (JAZZ) is Buying Shares


Today, a Director at Jazz Pharmaceuticals (JAZZ), Seamus Mulligan, bought shares of JAZZ for $7.23M.

Following this transaction Seamus Mulligan’s holding in the company was increased by 4.99% to a total of $158 million.

See today’s analyst top recommended stocks >>

Based on Jazz Pharmaceuticals’ latest earnings report for the quarter ending September 30, the company posted quarterly revenue of $469 million and quarterly net profit of $149 million. In comparison, last year the company earned revenue of $412 million and had a net profit of $63.53 million. JAZZ’s market cap is $8.61B and the company has a P/E ratio of 16.89. Currently, Jazz Pharmaceuticals has an average volume of 726.7K.

Based on 9 analyst ratings, the analyst consensus is Strong Buy with an average price target of $190.00, reflecting a 32.7% upside. Seven different firms, including BMO Capital and Wells Fargo, currently also have a Buy rating on the stock.

Seamus Mulligan’s trades have generated a -11.2% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts